RayKnowChina Research Map
Shortlist0

Qingdao University

青岛大学

QingdaoUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.7%Leads under 1 in 100 of China's research papers on NPC

Led 16 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
16
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025
ThemesEBV & screeningRadiotherapy techniqueRecurrent / metastatic disease

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Qingdao University3
  2. Yantai Yuhuangding Hospital3
  3. Qingdao Traditional Chinese Medicine Hospital1
  4. Child Health Care Hospital1
  5. Affiliated Weihai Hospital of Qingdao University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.3%Leads under 1 in 100 of China's research papers on ESCC

Led 9 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 332025
ThemesImmunotherapyMolecular markers & genomicsNeoadjuvant & combined treatment

Hospitals counted here

  1. Affiliated Hospital of Qingdao University8
  2. Affiliated Qingdao Central Hospital of Qingdao University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Development and validation of a prognostic model for first-line immunotherapy for metastatic esophageal squamous cell carcinoma.2026International immunopharmacology
  2. Comparing the Efficacy and Safety of IC-ICCRT-IO With CT-CCRT for Unresectable Locally Advanced ESCC: A Retrospective Analysis.2026Journal of immunotherapy (Hagerstown, Md. : 1997)
  3. Low Serum Interleukin-6 Levels Enhance the Efficacy of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.2025Cancer biotherapy & radiopharmaceuticals
  4. Trop2, Nectin-4, and PD-L1 expression profiles in esophageal squamous cell carcinoma: Implications for combined immunotherapy and ADC targeted therapies.2025Pathology, research and practice
  5. The efficacy and safety of induction chemotherapy combined with sintilimab followed by concurrent chemoradiotherapy plus sintilimab sequencing maintaining with sintilimab for patients with unresectable locally advanced e2025BMC cancerFree full text
Trials on ClinicalTrials.gov4
  1. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
  2. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
  3. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension StudyCompletedNCT03933449Study sitePhase 3Start 2016-12
  4. Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT01232374Study sitePhase 2Start 2010-09

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
0.7%Leads under 1 in 100 of China's research papers on HCC

Led 107 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
0
Research papers it led
107
Trials it led
2
Share of China's trials
0.1%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Qingdao University70
  2. Yantai Yuhuangding Hospital12
  3. Qingdao Municipal Hospital Counted in the group total4
  4. Affiliated Qingdao Municipal Hospital of Qingdao University Counted in the group total3
  5. Qingdao Municipal Hospital, Qingdao University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Tislelizumab plus tyrosine kinase inhibitors with TACE improves survival in unresectable hepatocellular carcinoma with clinical predictors and manageable safety.2025Frontiers in immunologyFree full text
  2. Radiomics-based machine-learning method to predict extrahepatic metastasis in hepatocellular carcinoma after hepatectomy: a multicenter study.2025Scientific reportsFree full text
  3. Analysis of the factors influencing liver regeneration after hepatectomy in hepatocellular carcinoma patients and the relationship between liver regeneration and prognosis.2025Scientific reportsFree full text
  4. Constructing a neural network model based on tumor-infiltrating lymphocytes (TILs) to predict the survival of hepatocellular carcinoma patients.2025PeerJFree full text
  5. Conventional transarterial chemoembolization followed by irreversible electroporation for hepatocellular carcinoma.2025BMC cancerFree full text
Trials on ClinicalTrials.gov6
  1. The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical StudyNot yet recruitingNCT07724951Study siteStart 2026-07
  2. TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal HypertensionNot yet recruitingNCT07350070Study sitePhase 2Start 2025-12
  3. Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High RiskNot yet recruitingNCT07010588Study siteN/AStart 2025-06
  4. Neutrophil Extracellular Traps as a Biomarker to Predict Portal Vein Tumor Thrombosis in Patients With Hepatocellular CarcinomaCompletedNCT05040347Lead sponsorStart 2020-08
  5. Predictive Model for Pain After TACECompletedNCT05545046Lead sponsorStart 2019-09
  6. Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04741165Study sitePhase 2Start 2021-01

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
1.7%Leads about 1 in 57 of China's research papers on Stomach cancer

Led 170 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
7
Research papers it led
170
Trials it led
19
Share of China's trials
1.3%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025
ThemesSurgeryImaging & AIChemotherapy & combined treatment

Hospitals counted here

  1. Affiliated Hospital of Qingdao University105
  2. Yantai Yuhuangding Hospital33
  3. Affiliated Taian City Central Hospital of Qingdao University Counted in the group total2
  4. Affiliated Qingdao Municipal Hospital of Qingdao University Counted in the group total1
  5. Qingdao Municipal Hospital1
  6. Weihai Central Hospital, Qingdao University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Three-year Survival Outcomes of Patients With Enhanced Recovery After Surgery Versus Conventional Care in Laparoscopic Distal Gastrectomy: The GISSG1901 Randomized Clinical Trial.2025Annals of surgeryRCTFree full text
  2. Identification and Categorization of Technical Errors and Hazard Zones of Robotic Versus Laparoscopic Total Gastrectomy for Gastric Cancer: A Single-center Prospective Randomized Controlled Study.2025Annals of surgeryRCTFree full text
  3. Short-term outcomes of preoperative computed tomography angiography versus standard assessment in patients with BMI ≥ 25.0 kg/m2 undergoing laparoscopic gastrectomy: the GISSG20-01 randomized clinical trial.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationRCT
  4. Impact and effect of preoperative short-term preoperative pulmonary-related training on patients with gastric cancer: a randomized controlled single center trial.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractRCT
  5. Effect of preoperative immunonutrition on postoperative short-term clinical outcomes in patients with gastric cancer cachexia: a prospective randomized controlled trial.2024World journal of surgical oncologyRCTFree full text
Trials on ClinicalTrials.gov6
  1. Home-based Whole Course Multimodal Prehabilitation Based on 5G + Artificial Intelligence Mobile HealthNot yet recruitingNCT07764523Lead sponsorN/AStart 2026-08
  2. Clinical Study on Using Laparoscopic Sentinel Lymph Node Navigation Combined With Dual Endoscopy Surgery for Early Gastric CancerRecruitingNCT07708012Lead sponsorN/AStart 2026-01
  3. TEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)RecruitingNCT07714980Lead sponsorN/AStart 2026-07
  4. Family-Supervised Prehabilitation to Reduce Postoperative Complications After Neoadjuvant Chemotherapy in Gastric CancerNot yet recruitingNCT07183358Lead sponsorN/AStart 2025-09
  5. TEAS for Gastrectomy RecoveryRecruitingNCT07898293Lead sponsorN/AStart 2024-10
  6. A Multicenter, RCT Study of the Clinical Efficacy of Robotic and Laparoscopic Gastrectomy in Neoadjuvant Gastric CancerRecruitingNCT06042998Lead sponsorN/AStart 2023-07

PubMed searchClinicalTrials.gov

Hepatoblastoma

肝母细胞瘤
4.5%Leads about 1 in 22 of China's research papers on Hepatoblastoma ▲ from 2.4%

Led 7 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.6%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.6%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 332025

Hospitals counted here

  1. Affiliated Hospital of Qingdao University6

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
1.3%Leads about 1 in 75 of China's research papers on Retinoblastoma ▼ from 2.7%

Led 4 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Yantai Yuhuangding Hospital2
  2. Affiliated Hospital of Qingdao University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
0.9%Leads under 1 in 100 of China's research papers on Osteosarcoma ▼ from 1.7%

Led 20 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
20
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 1120242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Qingdao University16
  2. Yantai Yuhuangding Hospital3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
1.9%Leads about 1 in 52 of China's research papers on Gastrointestinal stromal tumour

Led 10 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
10
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 332025

Hospitals counted here

  1. Affiliated Hospital of Qingdao University7
  2. Yantai Yuhuangding Hospital2
  3. Affiliated Taian Central Hospital of Qingdao University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
1.6%Leads about 1 in 63 of China's research papers on Neuroblastoma ▼ from 2.7%

Led 18 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
18
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 332025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Qingdao University9
  2. Children's Hospital, Qingdao University3
  3. Affiliated Taian City Central Hospital of Qingdao University1
  4. Yantai Yuhuangding Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
1.2%Leads about 1 in 81 of China's research papers on Ewing sarcoma New since 2021

Led 2 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Affiliated Hospital of Qingdao University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.6%Leads under 1 in 100 of China's research papers on Myeloma

Led 10 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
10
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 112025
ThemesDiagnosis, MRD & riskKidney & bone complicationsBispecific & antibody drugs

Hospitals counted here

  1. Affiliated Hospital of Qingdao University8
  2. Affiliated Qingdao Central Hospital, Qingdao University1
  3. Affiliate Hospital, Qingdao University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Deep learning and transformer-based feature fusion of conventional MRI for differentiating spinal osteolytic bone metastases and multiple myeloma.2026European journal of radiology
  2. Primary Systemic Amyloidosis Characterized by Multiple Keratinous Cysts: A Case Report.2025Journal of cutaneous pathology
  3. Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease.2024Scientific reportsFree full text
  4. Lumbar MR-based radiomics nomogram for detecting minimal residual disease in patients with multiple myeloma.2023European radiology
  5. Application of Capillary Electrophoresis in Monoclonal Gammopathies and the Cutoff Value of Monoclonal Protein in Differential Diagnosis of Multiple Myeloma and Other Monoclonal Gammopathies.2021Annals of clinical and laboratory science
Trials on ClinicalTrials.gov5
  1. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingNCT07555938Study sitePhase 3Start 2026-06
  2. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  3. A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaStatus unknownNCT05236621Study sitePhase 3Start 2021-01
  4. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  5. Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)TerminatedNCT01947309Study siteStart 2013-11

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
0.4%Leads under 1 in 100 of China's research papers on B-ALL New since 2021

Led 1 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.09%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025
ThemesPhiladelphia chromosome & geneticsChildren

Hospitals counted here

  1. Yantai Yuhuangding Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
1.9%Leads about 1 in 52 of China's research papers on Aplastic anaemia ▲ from 0.4%

Led 8 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 112025
ThemesStem cell transplantClonal evolution & PNHChildren

Hospitals counted here

  1. Affiliated Hospital of Qingdao University7
  2. Yantai Yuhuangding Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
1.0%Leads about 1 in 100 of China's research papers on HLH ▼ from 1.6%

Led 4 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 2220242025: 002025
ThemesLymphoma & cancer-related HLHTreatment regimensEBV & infection triggers

Hospitals counted here

  1. Affiliated Hospital of Qingdao University2
  2. Yantai Yuhuangding Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
0.4%Leads under 1 in 100 of China's research papers on Haemophilia A

Led 1 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.04%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
0.2%Leads under 1 in 100 of China's research papers on NMOSD New since 2021

Led 1 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
1
Research papers it led
1
Trials it led
1
Share of China's trials
1.3%
Share of the world's papers
0.05%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025
ThemesBiologic drugsAcute attack treatmentAntibodies & diagnosis

Hospitals counted here

  1. Affiliated Hospital of Qingdao University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgG4-related disease

IgG4相关性疾病
0.8%Leads under 1 in 100 of China's research papers on IgG4-RD ▼ from 2.0%

Led 2 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.1%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025
ThemesTreatment & relapsePancreas & bile ducts

Hospitals counted here

  1. Affiliated Hospital of Qingdao University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
0.6%Leads under 1 in 100 of China's research papers on Myasthenia gravis

Led 3 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
1
Research papers it led
3
Trials it led
1
Share of China's trials
1.1%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 222025
ThemesBiologic & complement drugsAntibodies & diagnosisStandard immunotherapy

Hospitals counted here

  1. Affiliated Hospital of Qingdao University2
  2. Yantai Yuhuangding Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
0.6%Leads under 1 in 100 of China's research papers on Moyamoya

Led 2 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025
ThemesRevascularisation surgeryImaging & blood flow

Hospitals counted here

  1. Affiliated Hospital of Qingdao University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Wilson disease

肝豆状核变性(Wilson 病)
1.0%Leads about 1 in 100 of China's research papers on Wilson disease New since 2021

Led 2 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.5%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025
ThemesGenetics (ATP7B)Diagnosis & copper tests

Hospitals counted here

  1. Affiliated Hospital of Qingdao University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.5%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis ▼ from 1.4%

Led 5 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 1120242025: 112025

Hospitals counted here

  1. Affiliated Hospital of Qingdao University3
  2. Affiliated Tai'an City Central Hospital of Qingdao University1
  3. Yantai Yuhuangding Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
0.8%Leads under 1 in 100 of China's research papers on Amyotrophic lateral sclerosis

Led 6 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.09%
Papers led per year
2021: 1120212022: 1120222023: 3320232024: 0020242025: 002025

Hospitals counted here

  1. Qingdao Municipal Hospital3
  2. Affiliated Hospital of Qingdao University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Alport syndrome

Alport 综合征
3.5%Leads about 1 in 29 of China's research papers on Alport syndrome New since 2021

Led 2 of 58 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

Hospitals counted here

  1. Affiliated Qingdao Municipal Hospital of Qingdao University1
  2. Yantai Yuhuangding Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
0.1%Leads under 1 in 100 of China's research papers on IgA nephropathy New since 2021

Led 1 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.06%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Affiliated Hospital of Qingdao University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
2.0%Leads about 1 in 50 of China's research papers on Primary biliary cholangitis

Led 6 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 2220242025: 112025

Hospitals counted here

  1. Affiliated Hospital of Qingdao University6

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary sclerosing cholangitis

原发性硬化性胆管炎
2.0%Leads about 1 in 50 of China's research papers on Primary sclerosing cholangitis New since 2021

Led 2 of 100 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Affiliated Hospital of Qingdao University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hereditary angioedema

遗传性血管性水肿
3.1%Leads about 1 in 32 of China's research papers on Hereditary angioedema New since 2021

Led 1 of 32 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (31.2%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Yantai Yuhuangding Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led1
  1. Hereditary angioedema-induced laryngeal edema: A diagnostic and therapeutic race against time.2025The American journal of emergency medicine
Trials on ClinicalTrials.gov2
  1. A Phase 2 in Adult Subjects With Hereditary AngioedemaActive, not recruitingNCT06846398Study sitePhase 2Start 2025-02
  2. A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)CompletedNCT05460325Study sitePhase 3Start 2022-06

PubMed searchClinicalTrials.gov